Top

Journal of Cardiothoracic Surgery

Published in:

Open Access 01-12-2021 | Esophageal Cancer | Research article

Effect of silencing C-erbB-2 on esophageal carcinoma cell biological behaviors by inhibiting IGF-1 pathway activation

Authors: Zhigao Niu, Wenping Zhang, Jialun Shi, Xiangdong Li, Hanlei Wu

Published in: Journal of Cardiothoracic Surgery | Issue 1/2021

Abstract

Objective

C-erbB-2 has been confirmed to be an oncogene that participates in cell growth, differentiation and division of tumors. We are wondered if its silenced expression can exert an anti-tumor effect. Therefore, this study is conducted to investigate the mechanism of C-erbB-2 silencing and IGF-1 pathway on esophageal carcinoma (EC) cell biological behaviors.

Methods

The objects of study were 84 EC patients from Heping Hospital Affiliated to Changzhi Medical College, with the collection of EC tissue and adjacent normal tissue (> 5 cm away from cancer tissue). C-erbB-2 protein expression in EC tissues was detected by immunohistochemistry. Human EC cell line Eca-109 was purchased from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. Based on different transfection protocols, EC cells with logarithmic growth phase of 3–5 passages were divided into blank control group, oe-C-erbB-2 NC group, siRNA C-erbB-2 NC group, oe-C-erbB-2 group, siRNA C-erbB-2 group, OSI-906 group, Rg5 group, Rg5 + siRNA C-erbB-2 NC group and Rg5 + siRNA C-erbB-2 group. Cell proliferation was detected by MTT assay; cell cycle distribution and apoptosis by flow cytometry; C-erbB-2, IGF-1, IGF-1R and Akt mRNA and protein expressions by qRT-PCR and western blot; and cell invasion and migration by Transwell assay and scratch test. Tumor growth was observed in male BALB/c nude mice (Shanghai Experimental Animal Center) based on Eca109 cell implantation, raising, and measurement.

Results

C-erbB-2, IGF-1, IGF-1R and Akt expression were higher in EC tissues than those in adjacent tissues (all P < 0.05). Compared with blank control group, both si-C-erbB-2 and OSI-906 groups had decreased IGF-1, IGF-1R and Akt mRNA and protein expressions, decreased cell proliferation, migration and invasion, prolonged G0/G1 phase, shortened S phase, increased cell apoptosis, and inhibited tumor growth (all P < 0.05); while opposite trends were detected in C-erbB-2 vector and Rg5 groups (all P < 0.05), without statistical differences in siRNA C-erbB-2 + Rg5 group (all P > 0.05).

Conclusion

Silencing C-erbB-2 expression may inhibit EC cell proliferation, promote cell apoptosis and block cell cycle progression by inhibiting IGF-1 pathway activation. The beneficial effect of silencing C-erbB-2 expression can be reversed by promoting the activation of IGF-1 pathway. Findings in our study may provide potential reference for understanding the molecular mechanism of EC and supply possible axis for preventing the development of EC from the perspective of molecular biology.

Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, et al. Oesophageal cancer. Nat Rev Dis Primers. 2017;3(1):17048. https://doi.org/10.1038/nrdp.2017.48.CrossRefPubMedPubMedCentral

Tustumi F, Bernardo WM, da Rocha JRM, Szachnowicz S, Seguro FC, Bianchi ET, et al. Esophageal achalasia: a risk factor for carcinoma. A systematic review and meta-analysis. Dis Esophagus. 2017;30(10):1–8. https://doi.org/10.1093/dote/dox072.CrossRefPubMed

Short MW, Burgers KG, Fry VT. Esophageal Cancer. Am Fam Physician. 2017;95(1):22–8.PubMed

Codipilly DC, Qin Y, Dawsey SM, Kisiel J, Topazian M, Ahlquist D, et al. Screening for esophageal squamous cell carcinoma: recent advances. Gastrointest Endosc. 2018;88(3):413–26. https://doi.org/10.1016/j.gie.2018.04.2352.CrossRefPubMedPubMedCentral

Monig S, et al. Early esophageal cancer: the significance of surgery, endoscopy, and chemoradiation. Ann N Y Acad Sci. 2018;1434(1):115–23. https://doi.org/10.1111/nyas.13955.CrossRefPubMed

Domper Arnal MJ, arenas AF, Arbeloa AL. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21(26):7933–43. https://doi.org/10.3748/wjg.v21.i26.7933.CrossRefPubMedPubMedCentral

Horie Y, Yoshio T, Aoyama K, Yoshimizu S, Horiuchi Y, Ishiyama A, et al. Diagnostic outcomes of esophageal cancer by artificial intelligence using convolutional neural networks. Gastrointest Endosc. 2019;89(1):25–32. https://doi.org/10.1016/j.gie.2018.07.037.CrossRefPubMed

Frater J, Lie D, Bartlett P, McGrath JJ. Insulin-like growth factor 1 (IGF-1) as a marker of cognitive decline in normal ageing: a review. Ageing Res Rev. 2018;42:14–27. https://doi.org/10.1016/j.arr.2017.12.002.CrossRefPubMed

Lee WS, Kim J. Insulin-like growth factor-1 signaling in cardiac aging. Biochim Biophys Acta Mol basis Dis. 2018;1864(5 Pt B):1931–8.CrossRef

10.

Shao P, Wang Y, Zhang M, Wen X, Zhang J, Xu Z, et al. The interference of DEHP in precocious puberty of females mediated by the hypothalamic IGF-1/PI3K/Akt/mTOR signaling pathway. Ecotoxicol Environ Saf. 2019;181:362–9. https://doi.org/10.1016/j.ecoenv.2019.06.017.CrossRefPubMed

11.

Zhou Y, Li S, Li J, Wang D, Li Q. Effect of microRNA-135a on cell proliferation, migration, invasion, apoptosis and tumor angiogenesis through the IGF-1/PI3K/Akt signaling pathway in non-small cell lung Cancer. Cell Physiol Biochem. 2017;42(4):1431–46. https://doi.org/10.1159/000479207.CrossRefPubMed

12.

Choucair A, Pham TH, Omarjee S, Jacquemetton J, Kassem L, Trédan O, et al. The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer. Oncogene. 2019;38(21):4015–27. https://doi.org/10.1038/s41388-019-0694-9.CrossRefPubMedPubMedCentral

13.

Chu PC, Lin PC, Wu HY, Lin KT, Wu C, Bekaii-Saab T, et al. Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. Oncogene. 2018;37(25):3440–55. https://doi.org/10.1038/s41388-018-0222-3.CrossRefPubMed

14.

Wang G, Lu M, Yao Y, Wang J, Li J. Esculetin exerts antitumor effect on human gastric cancer cells through IGF-1/PI3K/Akt signaling pathway. Eur J Pharmacol. 2017;814:207–15. https://doi.org/10.1016/j.ejphar.2017.08.025.CrossRefPubMed

15.

Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018;834:188–96. https://doi.org/10.1016/j.ejphar.2018.07.034.CrossRefPubMed

16.

Guan LY, Lu Y. New developments in molecular targeted therapy of ovarian cancer. Discov Med. 2018;26(144):219–29.PubMed

17.

Rong B, Yang S. Molecular mechanism and targeted therapy of Hsp90 involved in lung cancer: new discoveries and developments (review). Int J Oncol. 2018;52(2):321–36. https://doi.org/10.3892/ijo.2017.4214.CrossRefPubMed

18.

Kim JY, Cho CH, Song HS. Targeted therapy of ovarian cancer including immune check point inhibitor. Korean J Intern Med. 2017;32(5):798–804. https://doi.org/10.3904/kjim.2017.008.CrossRefPubMedPubMedCentral

19.

Song H, Zhu J, Lu D. Molecular-targeted first-line therapy for advanced gastric cancer. Cochrane Database Syst Rev. 2016;7:CD011461.PubMed

20.

Smith CIE, Blomberg P. Gene therapy - from idea to reality. Lakartidningen. 2017:114. https://lakartidningen.se/klinik-och-vetenskap-1/artiklar-1/klinisk-oversikt/2017/12/genterapi-fran-ide-till-verklighet/.

21.

Ono C, et al. Baculovirus as a Tool for Gene Delivery and Gene Therapy. Viruses. 2018;10(9):510–12. https://doi.org/10.3390/v10090510.

22.

Lara-Guerra H, Roth JA. Gene therapy for lung Cancer. Crit Rev Oncog. 2016;21(1–2):115–24. https://doi.org/10.1615/CritRevOncog.2016016084.CrossRefPubMedPubMedCentral

23.

Sun W, Shi Q, Zhang H, Yang K, Ke Y, Wang Y, et al. Advances in the techniques and methodologies of cancer gene therapy. Discov Med. 2019;27(146):45–55.PubMed

24.

Choong CJ, Baba K, Mochizuki H. Gene therapy for neurological disorders. Expert Opin Biol Ther. 2016;16(2):143–59. https://doi.org/10.1517/14712598.2016.1114096.CrossRefPubMed

25.

Goncalves GAR, Paiva RMA. Gene therapy: advances, challenges and perspectives. Einstein (Sao Paulo). 2017;15(3):369–75. https://doi.org/10.1590/s1679-45082017rb4024.CrossRef

26.

Han H. RNA interference to Knock down gene expression. Methods Mol Biol. 2018;1706:293–302. https://doi.org/10.1007/978-1-4939-7471-9_16.CrossRefPubMed

27.

Zotti M, dos Santos EA, Cagliari D, Christiaens O, Taning CNT, Smagghe G. RNA interference technology in crop protection against arthropod pests, pathogens and nematodes. Pest Manag Sci. 2018;74(6):1239–50. https://doi.org/10.1002/ps.4813.CrossRefPubMed

28.

Liu WR, Cao LR, Zuo GJ. Influence of chitosan nanoparticle-mediated C-erbB-2 gene silencing on invasion and apoptosis of Hep-2 cells. Genet Mol Res. 2016;15(4):gmr15048860. https://doi.org/10.4238/gmr15048860.

29.

Nie M, Qin Y, Zhu J, Li Y, Wang Z. Correlation between ultrasonic features and expression levels of C-erbB-2, VEGF and nm23 in breast cancer. Oncol Lett. 2018;16(2):1701–7. https://doi.org/10.3892/ol.2018.8777.CrossRefPubMedPubMedCentral

30.

Zhang Y, Li Y, Li H, Chen W, Liu W. Clostridium difficile toxin B recombinant protein inhibits tumor growth and induces apoptosis through inhibiting Bcl-2 expression, triggering inflammatory responses and activating C-erbB-2 and Cox-2 expression in breast cancer mouse model. Biomed Pharmacother. 2018;101:391–8. https://doi.org/10.1016/j.biopha.2018.02.045.CrossRefPubMed

31.

Saydam M, Yilmaz I. Effect of postoperative ischemia on steroid hormone receptors and c-erbB-2 levels in breast cancer tissue. Turk J Surg. 2018:1–5. Epub ahead of print. https://doi.org/10.5152/turkjsurg.2018.4001.

32.

Missaoui N, Landolsi H, Mestiri S, Essakly A, Abdessayed N, Hmissa S, et al. Immunohistochemical analysis of c-erbB-2, Bcl-2, p53, p21(WAF1/Cip1), p63 and Ki-67 expression in hydatidiform moles. Pathol Res Pract. 2019;215(3):446–52. https://doi.org/10.1016/j.prp.2018.12.015.CrossRefPubMed

33.

Akutsu Y, Murakami K, Kano M, Toyozumi T, Matsumoto Y, Takahashi M, et al. The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma. Esophagus. 2018;15(2):103–8. https://doi.org/10.1007/s10388-018-0604-1.CrossRefPubMed

34.

Fan L, Cao Q, Liu J, Zhang J, Li B. Circular RNA profiling and its potential for esophageal squamous cell cancer diagnosis and prognosis. Mol Cancer. 2019;18(1):16. https://doi.org/10.1186/s12943-018-0936-4.CrossRefPubMedPubMedCentral

35.

Toxopeus E, van der Schaaf M, van Lanschot J, Lagergren J, Lagergren P, van der Gaast A, et al. Outcome of patients treated within and outside a randomized clinical trial on Neoadjuvant Chemoradiotherapy plus surgery for esophageal Cancer: extrapolation of a randomized clinical trial (CROSS). Ann Surg Oncol. 2018;25(8):2441–8. https://doi.org/10.1245/s10434-018-6554-y.CrossRefPubMedPubMedCentral

36.

Vellayappan BA, et al. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. Cochrane Database Syst Rev. 2017;8:CD010511.PubMed

37.

Zhao M, Ang L, Huang J, Wang J. MicroRNAs regulate the epithelial-mesenchymal transition and influence breast cancer invasion and metastasis. Tumour Biol. 2017;39(2):1010428317691682. https://doi.org/10.1177/1010428317691682.CrossRefPubMed

38.

Zeng K, He B, Yang BB, Xu T, Chen X, Xu M, et al. The pro-metastasis effect of circANKS1B in breast cancer. Mol Cancer. 2018;17(1):160. https://doi.org/10.1186/s12943-018-0914-x.CrossRefPubMedPubMedCentral

39.

Zhou PJ, Xue W, Peng J, Wang Y, Wei L, Yang Z, et al. Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway. J Exp Clin Cancer Res. 2017;36(1):139. https://doi.org/10.1186/s13046-017-0609-y.CrossRefPubMedPubMedCentral

40.

Laudato S, Patil N, Abba ML, Leupold JH, Benner A, Gaiser T, et al. P53-induced miR-30e-5p inhibits colorectal cancer invasion and metastasis by targeting ITGA6 and ITGB1. Int J Cancer. 2017;141(9):1879–90. https://doi.org/10.1002/ijc.30854.CrossRefPubMed

41.

Zhong HH, Wang HY, Li J, Huang YZ. TRAIL-based gene delivery and therapeutic strategies. Acta Pharmacol Sin. 2019;40(11):1373–85. https://doi.org/10.1038/s41401-019-0287-8.CrossRefPubMedPubMedCentral

42.

Xin Y, Huang M, Guo WW, Huang Q, Zhang L, Jiang G. Nano-based delivery of RNAi in cancer therapy. Mol Cancer. 2017;16(1):134. https://doi.org/10.1186/s12943-017-0683-y.CrossRefPubMedPubMedCentral

43.

Denton AE, Roberts EW, Fearon DT. Stromal cells in the tumor microenvironment. Adv Exp Med Biol. 2018;1060:99–114. https://doi.org/10.1007/978-3-319-78127-3_6.CrossRefPubMed

44.

Benov L. Effect of growth media on the MTT colorimetric assay in bacteria. PLoS One. 2019;14(8):e0219713. https://doi.org/10.1371/journal.pone.0219713.CrossRefPubMedPubMedCentral

45.

Xia X, Wang X, Cheng Z, Qin W, Lei L, Jiang J, et al. The role of pyroptosis in cancer: pro-cancer or pro-"host"? Cell Death Dis. 2019;10(9):650. https://doi.org/10.1038/s41419-019-1883-8.CrossRefPubMedPubMedCentral

46.

Peltanova B, Raudenska M, Masarik M. Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review. Mol Cancer. 2019;18(1):63. https://doi.org/10.1186/s12943-019-0983-5.CrossRefPubMedPubMedCentral

47.

van de Merbel AF, et al. Protocols for migration and invasion studies in prostate Cancer. Methods Mol Biol. 2018;1786:67–79. https://doi.org/10.1007/978-1-4939-7845-8_4.CrossRefPubMed

Title: Effect of silencing C-erbB-2 on esophageal carcinoma cell biological behaviors by inhibiting IGF-1 pathway activation
Authors: Zhigao Niu
Wenping Zhang
Jialun Shi
Xiangdong Li
Hanlei Wu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Esophageal Cancer
Esophageal Cancer
Published in: Journal of Cardiothoracic Surgery / Issue 1/2021
Electronic ISSN: 1749-8090
DOI: https://doi.org/10.1186/s13019-021-01540-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effect of silencing C-erbB-2 on esophageal carcinoma cell biological behaviors by inhibiting IGF-1 pathway activation

Abstract

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Posterior pericardiotomy to prevent new-onset atrial fibrillation after coronary artery bypass grafting: a systematic review and meta-analysis of 10 randomized controlled trials

Application and effects of an early childhood education machine on analgesia and sedation in children after cardiothoracic surgery

Successful treatment of bilateral multiple pulmonary arteriovenous malformations in a patient with brain abscess and severe hypoxemia using a combination of transcatheter embolotherapy and surgical resection: a case report

Effects of seasonal and climate variations on in-hospital mortality and length of stay in patients with type A aortic dissection

Case–control study on the interplay between immunoparalysis and delirium after cardiac surgery

Novel hybrid treatment for extensive aortic arch aneurysms, a case report